Pseudo-Unitary Operators and Pseudo-Unitary Quantum Dynamics

We consider pseudo-unitary quantum systems and discuss various properties of pseudo-unitary operators. In particular we prove a characterization theorem for block-diagonalizable pseudo-unitary operators with finite-dimensional diagonal blocks. Furthermore, we show that every pseudo-unitary matrix is the exponential of $i=\sqrt{-1}$ times a pseudo-Hermitian matrix, and determine the structure of the Lie groups consisting of pseudo-unitary matrices. In particular, we present a thorough treatment of $2\times 2$ pseudo-unitary matrices and discuss an example of a quantum system with a $2\times 2$ pseudo-unitary dynamical group. As other applications of our general results we give a proof of the spectral theorem for symplectic transformations of classical mechanics, demonstrate the coincidence of the symplectic group $Sp(2n)$ with the real subgroup of a matrix group that is isomorphic to the pseudo-unitary group U(n,n), and elaborate on an approach to second quantization that makes use of the underlying pseudo-unitary dynamical groups.Comment: Revised and expanded version, includes an application to symplectic transformations and groups, accepted for publication in J. Math. Phy

Generalized Phase Space Representation of Operators

Introducing asymmetry into the Weyl representation of operators leads to a variety of phase space representations and new symbols. Specific generalizations of the Husimi and the Glauber-Sudarshan symbols are explicitly derivedComment: latex, 8 pages, expanded version accepted by J. Phys.

Hepatic melanomacrophage centers in the arctic cultured fish Cyclopterus lumpus are not indicative of its health state

publishedVersio

Quantum response of dephasing open systems

We develop a theory of adiabatic response for open systems governed by Lindblad evolutions. The theory determines the dependence of the response coefficients on the dephasing rates and allows for residual dissipation even when the ground state is protected by a spectral gap. We give quantum response a geometric interpretation in terms of Hilbert space projections: For a two level system and, more generally, for systems with suitable functional form of the dephasing, the dissipative and non-dissipative parts of the response are linked to a metric and to a symplectic form. The metric is the Fubini-Study metric and the symplectic form is the adiabatic curvature. When the metric and symplectic structures are compatible the non-dissipative part of the inverse matrix of response coefficients turns out to be immune to dephasing. We give three examples of physical systems whose quantum states induce compatible metric and symplectic structures on control space: The qubit, coherent states and a model of the integer quantum Hall effect.Comment: Article rewritten, two appendices added. 16 pages, 2 figure

Agricultural use of copper and its link to Alzheimer’s disease

Copper is an essential nutrient for plants, animals, and humans because it is an indispensable component of several essential proteins and either lack or excess are harmful to human health. Recent studies revealed that the breakdown of the regulation of copper homeostasis could be associated with Alzheimer’s disease (AD), the most common form of dementia. Copper accumulation occurs in human aging and is thought to increase the risk of AD for individuals with a susceptibility to copper exposure. This review reports that one of the leading causes of copper accumulation in the environment and the human food chain is its use in agriculture as a plant protection product against numerous diseases, especially in organic production. In the past two decades, some countries and the EU have invested in research to reduce the reliance on copper. However, no single alternative able to replace copper has been identified. We suggest that agroecological approaches are urgently needed to design crop protection strategies based on the complementary actions of the wide variety of crop protection tools for disease control

Optical tomography of Fock state superpositions

We consider optical tomography of photon Fock state superpositions in connection with recent experimental achievements. The emphasis is put on the fact that it suffices to represent the measured tomogram as a main result of the experiment. We suggest a test for checking the correctness of experimental data. Explicit expressions for optical tomograms of Fock state superpositions are given in terms of Hermite polynomials. Particular cases of vacuum and low photon-number state superposition are considered as well as influence of thermal noise on state purity is studied.Comment: 5 pages, 2 figure

Infrared conductivity of a one-dimensional charge-ordered state: quantum lattice effects

The optical properties of the charge-ordering ($CO$) phase of the one-dimensional (1D) half-filled spinless Holstein model are derived at zero temperature within a well-known variational approach improved including second-order lattice fluctuations. Within the $CO$ phase, the static lattice distortions give rise to the optical interband gap, that broadens as the strength of the electron-phonon ($el-ph$) interaction increases. The lattice fluctuation effects induce a long subgap tail in the infrared conductivity and a wide band above the gap energy. The first term is due to the multi-phonon emission by the charge carriers, the second to the interband transitions accompanied by the multi-phonon scattering. The results show a good agreement with experimental spectra.Comment: 5 figure

Classical and Quantum Systems: Alternative Hamiltonian Descriptions

In complete analogy with the classical situation (which is briefly reviewed) it is possible to define bi-Hamiltonian descriptions for Quantum systems. We also analyze compatible Hermitian structures in full analogy with compatible Poisson structures.Comment: To appear on Theor. Math. Phy

NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): From clinical trials to clinical practice

BACKGROUND: Pancreatic adenocarcinoma is an aggressive disease with poor prognosis. In a randomized phase III trial, combination of Nab-paclitaxel (Nab-P) plus gemcitabine showed superior activity and efficacy in first-line treatment compared with gemcitabine alone. METHODS: Nab-P is not dispensed in Italy; however, we obtained this drug from our Ethics Committee for compassionate use. The aim of this study was to evaluate the efficacy and safety profile of this Nab-P and gemcitabine combination in a cohort of patients treated outside clinical trials. From January 2012 to May 2014, we included 41 patients with advanced pancreatic adenocarcinoma receiving combination of 125 mg/m(2) Nab-P and 1 g/m(2) gemcitabine on days 1, 8 and 15 of a 28-day cycle, as first-line treatment. Median age of patients was 67 (range 41-77) years, and 11 patients were aged ≥70 years. RESULTS: Eastern Co-operative Oncology Group performance status was 0 or 1 in 32 patients (78 %) and 2 in nine patients (22 %). Primary tumor was located in the pancreatic head or body/tail in 24 (58.5 %) and 17 (41.5 %) patients, respectively, and nine patients had received biliary stent implantation before starting chemotherapy. Median carbohydrate antigen 19-9 level was 469 U/l (range 17.4-61546 U/l) and 29 patients (70.7 %) had referred pain at the time of diagnosis. Patients received a median six cycles (range 1-14) of treatment. Overall response rate was 36.6 %; median progression-free survival was 6.7 months [(95 % confidence interval (CI) 5.966-8.034), and median overall survival was 10 months (95 % CI 7.864-12.136). Treatment was well tolerated. No grade 4 toxicity was reported. Grade 3 toxicity included neutropenia in 10 patients (24.3 %), thrombocytopenia in five (12 %), anemia in three (7.3 %), diarrhea in four (9.7 %), nausea and vomiting in two (4.9 %), and fatigue in six (14.6 %). Finally, pain control was achieved in 24 of 29 patients (82.3 %) with a performance status improvement of 10 % according to the Karnofsky scale. CONCLUSIONS: Our results confirm that combination of gemcitabine plus Nab-P is effective both in terms of overall response rate, progression-free survival and overall survival, with a good safety profile.Background: Pancreatic adenocarcinoma is an aggressive disease with poor prognosis. In a randomized phase III trial, combination of Nab-paclitaxel (Nab-P) plus gemcitabine showed superior activity and efficacy in first-line treatment compared with gemcitabine alone. Methods: Nab-P is not dispensed in Italy; however, we obtained this drug from our Ethics Committee for compassionate use. The aim of this study was to evaluate the efficacy and safety profile of this Nab-P and gemcitabine combination in a cohort of patients treated outside clinical trials. From January 2012 to May 2014, we included 41 patients with advanced pancreatic adenocarcinoma receiving combination of 125 mg/m2 Nab-P and 1 g/m2 gemcitabine on days 1, 8 and 15 of a 28-day cycle, as first-line treatment. Median age of patients was 67 (range 41-77) years, and 11 patients were aged ≥70 years. Results: Eastern Co-operative Oncology Group performance status was 0 or 1 in 32 patients (78 %) and 2 in nine patients (22 %). Primary tumor was located in the pancreatic head or body/tail in 24 (58.5 %) and 17 (41.5 %) patients, respectively, and nine patients had received biliary stent implantation before starting chemotherapy. Median carbohydrate antigen 19-9 level was 469 U/l (range 17.4-61546 U/l) and 29 patients (70.7 %) had referred pain at the time of diagnosis. Patients received a median six cycles (range 1-14) of treatment. Overall response rate was 36.6 %; median progression-free survival was 6.7 months [(95 % confidence interval (CI) 5.966-8.034), and median overall survival was 10 months (95 % CI 7.864-12.136). Treatment was well tolerated. No grade 4 toxicity was reported. Grade 3 toxicity included neutropenia in 10 patients (24.3 %), thrombocytopenia in five (12 %), anemia in three (7.3 %), diarrhea in four (9.7 %), nausea and vomiting in two (4.9 %), and fatigue in six (14.6 %). Finally, pain control was achieved in 24 of 29 patients (82.3 %) with a performance status improvement of 10 % according to the Karnofsky scale. Conclusions: Our results confirm that combination of gemcitabine plus Nab-P is effective both in terms of overall response rate, progression-free survival and overall survival, with a good safety profile

NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): From clinical trials to clinical practice

Background: Pancreatic adenocarcinoma is an aggressive disease with poor prognosis. In a randomized phase III trial, combination of Nab-paclitaxel (Nab-P) plus gemcitabine showed superior activity and efficacy in first-line treatment compared with gemcitabine alone. Methods: Nab-P is not dispensed in Italy; however, we obtained this drug from our Ethics Committee for compassionate use. The aim of this study was to evaluate the efficacy and safety profile of this Nab-P and gemcitabine combination in a cohort of patients treated outside clinical trials. From January 2012 to May 2014, we included 41 patients with advanced pancreatic adenocarcinoma receiving combination of 125 mg/m2 Nab-P and 1 g/m2 gemcitabine on days 1, 8 and 15 of a 28-day cycle, as first-line treatment. Median age of patients was 67 (range 41-77) years, and 11 patients were aged ≥70 years. Results: Eastern Co-operative Oncology Group performance status was 0 or 1 in 32 patients (78 %) and 2 in nine patients (22 %). Primary tumor was located in the pancreatic head or body/tail in 24 (58.5 %) and 17 (41.5 %) patients, respectively, and nine patients had received biliary stent implantation before starting chemotherapy. Median carbohydrate antigen 19-9 level was 469 U/l (range 17.4-61546 U/l) and 29 patients (70.7 %) had referred pain at the time of diagnosis. Patients received a median six cycles (range 1-14) of treatment. Overall response rate was 36.6 %; median progression-free survival was 6.7 months [(95 % confidence interval (CI) 5.966-8.034), and median overall survival was 10 months (95 % CI 7.864-12.136). Treatment was well tolerated. No grade 4 toxicity was reported. Grade 3 toxicity included neutropenia in 10 patients (24.3 %), thrombocytopenia in five (12 %), anemia in three (7.3 %), diarrhea in four (9.7 %), nausea and vomiting in two (4.9 %), and fatigue in six (14.6 %). Finally, pain control was achieved in 24 of 29 patients (82.3 %) with a performance status improvement of 10 % according to the Karnofsky scale. Conclusions: Our results confirm that combination of gemcitabine plus Nab-P is effective both in terms of overall response rate, progression-free survival and overall survival, with a good safety profile